11C-Methionine PET as Prognostic Marker of Gliomas
Launched by ISTITUTO CLINICO HUMANITAS · Aug 5, 2015
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
This is a retrospective observation that involves the revision of clinical, instrumental and pathologic data of an estimated cohort of 145 patients with glioma treated with surgery with radical intent at our center.
We will review 11C-Methionine PET data acquired within 30 days prior to surgery and analyze its principal imaging characteristics with respect to IDH1 mutation status, MGMT promoter methylation and 1p/19q co-deletion. These markers will be studied on tumor tissue obtained at surgery, used for diagnostic purposes and stored in paraffin.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of glioma
- • 11C-Methionine within 30 days before surgery
- Exclusion Criteria:
- • Absence of tumor specimen
- • No clinical data
- • 11C-Methionine can not be evaluated
About Istituto Clinico Humanitas
Istituto Clinico Humanitas is a leading clinical research organization based in Italy, dedicated to advancing medical science through innovative clinical trials and research initiatives. With a strong emphasis on patient-centered care and cutting-edge methodologies, the institute collaborates with various stakeholders in the healthcare sector to develop and evaluate new therapies and treatment protocols. Its multidisciplinary team of experts is committed to ensuring the highest standards of ethical practice and scientific rigor, contributing to significant advancements in medical knowledge and improved patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rozzano, Milano, Italy
Patients applied
Trial Officials
Egesta Lopci, MD
Principal Investigator
Humanitas Clinical and Research Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials